<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37379801</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2212-1102</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Value in health regional issues</Title><ISOAbbreviation>Value Health Reg Issues</ISOAbbreviation></Journal><ArticleTitle>Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.</ArticleTitle><Pagination><StartPage>88</StartPage><EndPage>96</EndPage><MedlinePgn>88-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vhri.2023.03.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2212-1099(23)00039-0</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study aimed to describe the healthcare resource utilization (HCRU) and healthcare costs associated with systemic lupus erythematosus (SLE) management in China from the patient's and the payer's perspective.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">HCRU and medical costs (2017 US dollar [USD]) between January 1 and December 31, 2017, were extracted from the national medical insurance claims database, China Health Insurance Research Association (consisting of claims from all public health insurance schemes in China), for adults with &#x2265; 1 SLE-related claim. The main analysis group comprised all adults with an SLE diagnosis and claim during 2017 (overall group); the annual subgroup (SLE diagnosis and claim in January 2017) informed annual HCRU and costs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall group consisted of 3645 adults with &#x2265; 1 SLE-related claim. Outpatient visits constituted 86.9% of healthcare visits. SLE-related healthcare outpatient costs were USD 433 per outpatient, and inpatient costs were USD 2072 per inpatient. Medication costs accounted for 75.0% (USD 42/56) of total costs for outpatient visits and 44.3% (USD 456/1030) for inpatient hospitalizations. Notably, 35.4% of patients had a severe SLE flare; mean SLE-related cost per severe flare was USD 1616. HCRU and costs were similar in the annual subgroup. Female sex, SLE flares, tertiary hospitals, renal involvement, and utilization of anti-infective drugs were associated with higher SLE-related patient costs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SLE in China is associated with considerable HCRU and medical costs, especially for patients experiencing severe SLE flares. Preventing organ involvement, infections, flares, and associated hospitalizations may reduce the burden on patients and healthcare providers in China.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Value, Evidence and Outcomes, GSK, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lloyd</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Value, Evidence and Outcomes, GSK, Twickenham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Selin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Value, Evidence and Outcomes, GSK, Twickenham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Beijing Brainpower Pharma Consulting Co. Ltd., Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chauhan</LastName><ForeName>Deven</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Value, Evidence and Outcomes, GSK, Brentford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juliao</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Value, Evidence and Outcomes, GSK, Collegeville, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quasny</LastName><ForeName>Holly</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Sciences, GSK, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Chunde</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Electronic address: baochunde_1678@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Value Health Reg Issues</MedlineTA><NlmUniqueID>101592642</NlmUniqueID><ISSNLinking>2212-1099</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="Y">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007348" MajorTopicYN="N">Insurance, Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016527" MajorTopicYN="N">Drug Costs</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">China Health Insurance Research Association</Keyword><Keyword MajorTopicYN="N">Chinese population</Keyword><Keyword MajorTopicYN="N">claims analysis</Keyword><Keyword MajorTopicYN="N">cost of illness</Keyword><Keyword MajorTopicYN="N">observational study</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>29</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>18</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37379801</ArticleId><ArticleId IdType="doi">10.1016/j.vhri.2023.03.007</ArticleId><ArticleId IdType="pii">S2212-1099(23)00039-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>